Patents by Inventor Hans E. Wiedermann

Hans E. Wiedermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Piperidinesulfonylurea derivatives
    Patent number: 4052507
    Abstract: A series of novel 1-piperidinesulfonylurea compounds derived from a pyrimidine monocarboxylic acid have been prepared by reacting an appropriate sulfamide with an organic isocyanate or a trisubstituted urea equivalent thereof. The sulfamylureas so obtained are useful in therapy as oral hypoglycemic agents. Typical members include those compounds derived from 1,3-dimethyl-1,2,3,4-tetrahydropyrimidine-2,4-dione-5-carboxylic acid, of which 1-(bicyclo[2.2.1]hept-5-en-2-yl-endo-methyl)-3-{4-[2-(1,3-dimethyl-1,2,3,4 -tetrahydropyrimidine-2,4-dione-5-carboxamido)ethyl]-1-piperidinesulfonyl}u rea is a most preferred embodiment.
    Type: Grant
    Filed: September 24, 1976
    Date of Patent: October 4, 1977
    Assignee: Pfizer Inc.
    Inventor: Hans E. Wiedermann
  • 4-[2-(1,3-Dialkyl-1 ,2,3,4-tetra-hydropyrimidine-2,4-dione-5-carboxamido)ethyl]-1-piperidine sulfonamide
    Patent number: 3998828
    Abstract: A series of novel 1-piperidinesulfonylurea compounds derived from a pyrimidine monocarboxylic acid have been prepared by reacting an appropriate sulfamide with an organic isocyanate or a trisubstituted urea equivalent thereof. The sulfamylureas so obtained are useful in therapy as oral hypoglycemic agents. Typical members include those compounds derived from 1,3-dimethyl-1,2,3,4-tetrahydropyrimidine-2,4-dione-5-carboxylic acid, of which 1-(bicyclo[2.2.1]hept-5-en-2-yl-endo-methyl)-3-{4-[2-(1,3-dimethyl-1,2,3,4 -tetrahydropyrimidine-2,4-dione-5-carboxamido)ethyl]-1-piperidinesulfonyl} urea is a most preferred embodiment.
    Type: Grant
    Filed: November 7, 1975
    Date of Patent: December 21, 1976
    Assignee: Pfizer Inc.
    Inventor: Hans E. Wiedermann
  • Composition comprising a benzenesulfonylurea hypoglycemic agent and method of treatment
    Patent number: 3961067
    Abstract: Several benzenesulfonylurea compounds derived from 4-methyl-5-thiazolecarboxylic acid have been prepared by reacting 4-[2-(4-methyl-5-thiazolecarboxamido)ethyl]benzenesulfonamide with an appropriate organic isocyanate or a trisubstituted urea equivalent thereof. The sulfonylureas so obtained are useful in therapy as oral hypoglycemic agents. 1-Cyclohexyl-3-{4-[2-(4-methyl-5-thiazolecarboxamido)ethyl]benzenesulfonyl }urea represents a preferred embodiment.
    Type: Grant
    Filed: October 21, 1974
    Date of Patent: June 1, 1976
    Assignee: Pfizer Inc.
    Inventors: Donald E. Kuhla, Reinhard Sarges, Hans E. Wiedermann
  • Piperidinesulfonylurea derivatives
    Patent number: 3936455
    Abstract: A series of novel 1-piperidinesulfonylurea compounds derived from a pyrimidine monocarboxylic acid have been prepared by reacting an appropriate sulfamide with an organic isocyanate or a trisubstituted urea equivalent thereof. The sulfamylureas so obtained are useful in therapy as oral hypoglycemic agents. Typical members include those compounds derived from 1,3-dimethyl-1,2,3,4-tetrahydropyrimidine-2,4-dione-5-carboxylic acid, of which 1-(bicyclo[2.2.1]hept-5-en-2-yl-endo-methyl)-3-{4-[2-(1,3-dimethyl-1,2,3,4 -tetrahydropyrimidine-2,4-dione-5-carboxamido)ethyl]-1-piperidinesulfonyl} urea is a most preferred embodiment.
    Type: Grant
    Filed: January 31, 1975
    Date of Patent: February 3, 1976
    Assignee: Pfizer Inc.
    Inventor: Hans E. Wiedermann